Suzhou Erye Of China To Lose 51% Stakeholder NeoStem Of U.S.
This article was originally published in PharmAsia News
Executive Summary
China's Suzhou Erye Pharmaceutical generics maker is losing its majority stakeholder, as U.S.-based NeoStem offers its 51% stake for sale for $12.3 million.